D283 Med Xenograft Model Service for Medulloblastoma

The D283 Med xenograft model represents one of the most widely utilized preclinical platforms for studying Group 3/Group 4 medulloblastoma, offering researchers a robust system to evaluate therapeutic efficacy against this aggressive pediatric brain tumor. Alfa Cytology provides comprehensive D283 Med xenograft model services tailored to your specific drug discovery and development needs, from tumor inoculation and monitoring to endpoint analysis and histopathological evaluation.

Overview of D283 Med Xenograft Model for Medulloblastoma

Medulloblastoma is the most common malignant brain tumor in children, arising from the cerebellum or posterior fossa. The D283 Med cell line was established in 1985 by Friedman et al. from malignant ascites cells and peritoneal metastasis of a 6-year-old male patient with metastatic medulloblastoma. Genetically, D283 Med exhibits characteristics of both Group 3 and Group 4 medulloblastoma subtypes, featuring MYC proto-oncogene overexpression and isochromosome 17q (i17q), a hallmark chromosomal aberration associated with these high-risk subgroups. The cell line demonstrates a mixed growth pattern, forming multicellular aggregates in suspension with some adherent cells, and exhibits a population doubling time of approximately 52.55 hours in vitro.

In xenograft settings, D283 Med cells form serially transplantable tumors in immunodeficient mice, including both intracranial (orthotopic) and subcutaneous models. Intracranial tumors display histological features consistent with medulloblastoma, including small cells with scant cytoplasm, abundant mitotic figures, and prominent anuclear zones resembling neuroblastic rosettes. The model expresses key neural markers including glutamine synthetase, neuron-specific enolase, and neurofilament proteins, while remaining negative for glial fibrillary acidic protein (GFAP) and S-100 protein. D283 Med is particularly valuable for studying cancer stem cell biology, as it exhibits high CD133 expression and robust medullosphere formation capacity, making it instrumental for investigating tumor-initiating cell populations and therapeutic resistance mechanisms.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting Group 3/Group 4 medulloblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving medulloblastoma progression and cancer stem cell biology, and how treatments intersect with MYC-driven oncogenic signaling.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for CD133-positive tumor-initiating cells.

Figure 1. Morphology, selected markers and responses to ionizing radiation in the human medulloblastoma cell lines. (Bartek Jr, Jiri, et al., 2020)

Cell Line Information: D283 Med

The D283 Med cell line is a well-established human medulloblastoma line with comprehensive molecular characterization. Its mixed Group 3/Group 4 molecular characteristics and cancer stem cell properties make it unique among available medulloblastoma cell lines and essential for preclinical research targeting high-risk pediatric brain tumor subtypes.

Our Services

Alfa Cytology leverages the D283 Med xenograft model to deliver high-quality, reproducible preclinical data for your medulloblastoma therapeutic programs. Our experienced team ensures rigorous quality control, standardized tumor monitoring protocols, and comprehensive endpoint analysis to accelerate your drug development pipeline. Whether you require subcutaneous or orthotopic implantation, bioluminescent imaging, or combination therapy studies, Alfa Cytology provides end-to-end support with flexible study designs and timely data delivery.

Workflow of D283 Med Xenograft Model Construction

The construction of a D283 Med xenograft model follows a systematic, multi-step workflow designed to ensure reproducible tumor growth, reliable data acquisition, and ethical compliance. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Preparation and Quality Control: D283 Med cells are expanded in culture under standard conditions (EMEM with 10% FBS, 37 degrees C, 5% CO2) and authenticated via STR profiling prior to inoculation. Mycoplasma testing and viability assessment are performed to ensure cell quality.
2. Recipient Mouse Selection and Preparation: Immunodeficient mice (commonly NOD-SCID or NSG) are selected based on study requirements. Animals are acclimatized for at least one week and randomized into treatment groups prior to tumor cell injection.
3. Tumor Cell Inoculation: For subcutaneous models, 5-6 x 10^6 D283 Med cells suspended in 200 uL of Matrigel or PBS are injected into the flank. For orthotopic models, 5 x 10^4 cells are stereotactically injected into the cerebellum to mimic natural tumor localization.
4. Tumor Monitoring and Growth Assessment: Subcutaneous tumors are measured with calipers twice weekly using the formula V = (length x width^2)/2. Orthotopic tumors are monitored via bioluminescent imaging (BLI) for non-invasive longitudinal tracking of tumor burden.
5. Treatment Administration: Test compounds are administered according to the study protocol (oral gavage, intravenous, intraperitoneal, or intratumoral injection). Dosing schedules and routes are optimized based on compound pharmacokinetics and study objectives.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC), molecular analysis (RNA/DNA extraction), and biomarker evaluation. Survival data and body weight changes are recorded throughout the study.

Figure 2: Schematic workflow illustrating the derivation and construction of the D283 Med Xenograft Model at Alfa Cytology.

Case Study-D283 Med Xenograft Model Development

Alfa Cytology has successfully established and validated the D283 Med xenograft model across multiple preclinical studies, demonstrating consistent tumor take rates, predictable growth kinetics, and responsiveness to standard-of-care reference compounds. Our internal datasets show robust tumor engraftment with measurable latency periods and doubling times aligned with published literature. Detailed efficacy data, pharmacodynamic profiles, and histopathological readouts are available upon request under appropriate confidentiality agreements. Contact our team to discuss how our validated D283 Med model can be integrated into your specific therapeutic development program.

Why Choose Alfa Cytology?

Alfa Cytology offers a differentiated preclinical service experience built on scientific rigor, operational transparency, and client-centric flexibility. Our D283 Med xenograft model service is designed to deliver actionable data with minimal turnaround time.

• Verified Cell Line Integrity: Validated, authenticated D283 Med cell stocks with documented STR profiles and regular mycoplasma screening.
• High Take Rates and Consistency: Experienced surgical team capable of both subcutaneous and orthotopic (intracranial) implantation with high success rates.
• Comprehensive Analytical Support: Integrated bioluminescent imaging capability for real-time, non-invasive tumor monitoring in orthotopic models.
• Tailored Study Designs: Customizable study designs including single-agent, combination, dose-response, and pharmacokinetic-pharmacodynamic (PK/PD) evaluations.
• Standardized Protocols: Comprehensive endpoint analysis encompassing tumor volume, survival curves, body weight monitoring, histopathology, and molecular biomarker assessment.
• Dedicated Project Management: Dedicated project management with regular progress updates, raw data delivery, and interpretive reporting to support regulatory submissions.

Contact Us

Ready to advance your medulloblastoma therapeutic program with a validated D283 Med xenograft model? Contact us today to discuss your study requirements, timeline, and budget. Our scientific team is prepared to design a customized preclinical strategy that aligns with your development goals. Please reach out to us today via our inquiry form or email to learn more about our D283 Med Xenograft Model services.

For research use only. Not intended for any clinical use.